|
It is estimated that central nervous system disorders affect approximately 1.5 billion people worldwide. Aging population and the improved understanding of psychiatric disorders result in an increasing need for viable treatments. Finding a cure or a control for a variety of CNS disorders represents an ever-growing challenge for the pharmaceutical industry, and it is one of the fastest growing and largest therapeutic areas facing the industry today. The 6th Annual Clinical Trials in CNS Conference offers a unique opportunity to hear about the latest developments from industry leaders,
providing insights on design, management and assessment of clinical trials for CNS targets. A panel of industry and academic experts will explore a range of timely topics: - Prediction of Human Efficacy in Animal Models
- Paediatric CNS Clinical Trials and the European Paediatric Committee
- Microdosing Clinical Studies for CNS Drug Design
- Imaging Analysis: Monitoring and Predictive Capabilities
- Patient Recruitment for CNS Clinical Trials
- Pharmacogenetic Approaches and Diagnostic Tests
Confirmed Speakers Include: - Dr Tanya Ramey, Clinical Lead, Neurosciences, Pfizer
- Dr Mark Schmidt, Director and Clinical Expert, CNS, Johnson& Johnson
- Dr Judith Dunn, Senior Medical Director, CNS, Sepracor
- Dr Michel Dib , Medical Director, CNS, Sanofi-Aventis
- Dr Paul Thompson, CPDM-Neurology Biomarker Group, GlaxoSmithKline
Who Should Attend the SMi Clinical Trials in CNS Conference? - Medical Directors
- Director of Metabolic Diseases
- Senior Scientists - CNS Diseases
- Directors of Clinical Research
- Senior Clinical Project Managers
For Speaking opportunities please contact Venus Simbulan at vsimbulan@smi-online.co.uk For Sponsorship opportunities please contact Alia Malick at amalick@smi-online.co.uk
|
Events Home Page
